Abstract:Cumulative evidence from both in vitro and animal studies suggests that cyclooxygenase-2 (COX-2) may be involved in the development and progression of lung cancer. Overproduction of prostaglandin E synthase and prostaglandin E 2 (PGE 2 ), one of the end products of the COX-2 pathway, has been implicated in the pathogenesis of non-small cell lung cancer. On the other hand, evidence suggests that prostacyclin (PGI 2 ), another end products of the COX-2 pathway, may differ from other bioactive prostaglandins and may exert cancer-inhibitory effects on the development of lung cancer. PGE 2 is quickly converted to 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), a major PGE 2 metabolite and excreted in urine. PGI 2 is rapidly converted into 6-keto-PGF 1a , a chemically stable but biologically inactive hydration product. Circulatory 6-keto-PGF 1a undergoes s-oxidation and appears in the urine as 2,3-dinor-6-keto-PGF 1a (PGI-M), the primary breakdown product of PGI 2 . Urinary PGE-M and PGI-M are stable compounds and can be measured accurately and reliably with newly developed and validated LC-MS and GC-MS assays. In this study, we evaluated the association of pre-diagnostic urinary PGE-M and PGI-M levels with subsequent risk of developing lung cancer. We conducted a nested case-control study using resources of the Shanghai Men9s Health Study, a prospective cohort study, in which 61,491 Chinese men aged 40-74 years were recruited from 2002 to 2006 and followed for up to 7 years. Urinary PGE-M and PGI-M in 349 incident lung cancer patients were compared to 349 matched controls. Overall, the geometric mean of baseline level of urinary PGE-M did not differ significantly between cases and controls. Compared with the lowest quartile, the risks (odds ratios, ORs) of developing lung cancer were non-significantly elevated (1.48, 95% CI=0.91-2.40 for the highest quartile). No dose-response relationship was evident. The baseline level of urinary PGI-M was more than 20% higher in cases than in controls. The ORs for developing lung cancer increased from 1.0 to 1.14 (95% CI=0.66-1.95), 1.45 (95% CI=0.86-2.45), and 1.70 (95% CI=0.99-2.92) across the quartiles of urinary PGI-M levels (P for trend=0.0056). Excluding 63 case-control pairs who were diagnosed with lung cancer within one year of follow-up did not change the associations for PGE-M and PGI-M. No interaction was found between PGE-M and PGI-M in relation to lung cancer risk. In summary, using data from a large prospective cohort study, we found that high levels of urinary PGI-M, and possibly PGE-M, were associated with subsequent risk of developing lung cancer. Our data suggest that high activity of the COX-2 pathway, rather than the prostaglandin E 2 alone, may play a major role in lung cancer development. Further studies are needed to evaluate these two urinary markers as possible biomarkers for lung cancer risk assessment. Citation Format: Qiuyin Cai, Yong-Bing Xiang, Wanqing Wen, Ginger L. Milne, Hong-Lan Li, Jie Wu, Gong Yang, Jing Gao, Tsogzolmaa Dorjgochoo, Yu-Tang Gao, Wei Zheng, Xiao Ou Shu. Prospective study of urinary prostaglandin E 2 and prostacyclin metabolites and lung cancer risk . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 122. doi:10.1158/1538-7445.AM2013-122

Prospective Study Of Urinary Prostaglandin E-2 Metabolite And Colorectal Cancer Risk

Prospective Study of Urinary Prostaglandin E<sub>2</sub> Metabolite and Colorectal Cancer Risk

Prospective Study of Urinary Prostaglandin E2 Metabolite and Pancreatic Cancer Risk

Urinary Prostaglandin E2 Metabolite and Breast Cancer Risk

Urinary Prostaglandin E-2 Metabolite and Gastric Cancer Risk in the Shanghai Women'S Health Study

Abstract 2790: Prospective Study of Urinary Prostaglandin E2 Metabolite and Lung Cancer Risk

Urinary Prostaglandin E2 Metabolite and Risk for Colorectal Adenoma

Correlation between Metabolite of Prostaglandin E2 and the incidence of colorectal adenomas

A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter Pylori Antibodies, and Gastric Cancer Risk.

Abstract 122: Prospective study of urinary prostaglandin E 2 and prostacyclin metabolites and lung cancer risk .

Abstract 2272: A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter Pylori Antibodies, and Gastric Cancer Risk

Urinary Prostaglandin E2 Metabolite and Pancreatic Cancer Risk: Case-Control Study in Urban Shanghai.

Abstract 2681: Prediagnostic levels of urinary 8-<i>epi</i>-prostaglandin F<sub>2α</sub>and prostaglandin E<sub>2</sub>metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma

A prospective study of dietary polyunsaturated fatty acids and colorectal cancer risk in Chinese women.

Urinary prostaglandin E2 as a biomarker for recurrent UTI in postmenopausal women

Prediagnostic Levels of Urinary 8-Epi-prostaglandin F2α and Prostaglandin E2 Metabolite, Biomarkers of Oxidative Damage and Inflammation, and Risk of Hepatocellular Carcinoma.

Circulating Prostaglandin Biosynthesis in Colorectal Cancer and Potential Clinical Significance.

Polycyclic aromatic hydrocarbons: determinants of urinary 1-hydroxypyrene glucuronide concentration and risk of colorectal cancer in the Shanghai Women’s Health Study

Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis

Association Of Genetic Polymorphisms In The Cox-2 (Ptgs2), Prostaglandin E Synthase (Ptges), And Prostacyclin Synthase (Ptgis) Genes With Risk Of Breast Cancer.

CYP24A1 Variant Modifies the Association Between Use of Oestrogen Plus Progestogen Therapy and Colorectal Cancer Risk